Cell Freezing Media Market Report 2026

The cell freezing media market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $1.97 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to expansion of biobanking activities, increased use of cryopreservation in research, growth in stem cell research programs, rising adoption of controlled-rate freezing methods, increased availability of liquid nitrogen storage facilities.

The cell freezing media market size is expected to see rapid growth in the next few years. It will grow to $3 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing development of cell and gene therapies, rising demand for large-scale cell banking, expansion of personalized medicine research, growing regulatory requirements for cell storage quality, increasing adoption of automated cryopreservation systems. Major trends in the forecast period include increasing adoption of ready-to-use cryopreservation media, rising demand for serum-free freezing media, growing use of gmp-grade cryoprotectants, expansion of long-term cell banking practices, enhanced focus on post-thaw cell recovery.

The growing demand for personalized medicine is expected to drive the expansion of the cell freezing media market in the coming years. Personalized medicine is a healthcare approach that customizes treatments for individual patients based on their genetic makeup, environmental exposure, and lifestyle factors to achieve better clinical outcomes. The increasing demand for personalized medicine is largely attributed to advances in genomic technologies, which allow for accurate identification of genetic variations and the development of individualized treatment strategies. Cell freezing media supports personalized medicine by offering dependable cryopreservation solutions that safeguard patient-specific cells, tissues, and biological materials. These media ensure high post-thaw cell viability and functionality, enabling the development of customized therapies and improving overall treatment effectiveness. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, representing a notable rise from the 12 approvals recorded in 2022. Therefore, the increasing demand for personalized medicine is contributing to the growth of the cell freezing media market.

Leading companies operating in the cell freezing media market are concentrating on the development of advanced solutions such as specialized cryopreservation media to improve efficiency, enhance cell survival, and accelerate therapeutic development. Specialized cryopreservation media are carefully formulated solutions designed to preserve cells, tissues, or biological materials at ultra-low temperatures while maintaining their structural integrity, viability, and functional properties. For instance, in April 2024, Pluristyx Inc., a US-based biotechnology company, introduced PluriFreeze, a xeno-free and serum-free cryopreservation medium manufactured under cGMP conditions. The product is designed to enhance post-thaw recovery and functionality across a broad range of cell types, including stem cells and immune cells. PluriFreeze offers a robust, ready-to-use formulation that supports consistent performance, high cell viability, and seamless transition of therapies from research to clinical applications, while improving manufacturing efficiency and reproducibility in cell and gene therapy development.

In April 2025, BioLife Solutions Inc., a US-based biotechnology company, acquired PanTHERA CryoSolutions Inc. for an undisclosed amount. Through this acquisition, BioLife Solutions expanded its cryopreservation media capabilities by gaining access to PanTHERA’s proprietary ice recrystallization inhibitor (IRI) technology. This enhancement strengthens BioLife Solutions’ product portfolio while improving cryopreservation performance, broadening research applications, and increasing customer value in cell and gene therapy biomanufacturing. PanTHERA CryoSolutions Inc. is a Canada-based biotechnology company specializing in the development and production of cell freezing media and cryopreservation solutions.

Major companies operating in the cell freezing media market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, FUJIFILM Corporation, Lonza Group Ltd., Avantor Inc., Sartorius AG, BioRad Laboratories Inc., BioTechne Corporation, Miltenyi Biotec GmbH, Stemcell Technologies Inc., Vitrolife AB, American Type Culture Collection (ATCC), Bio-Life Solutions Inc., Nacalai Tesque Inc., PromoCell GmbH, Nippon Genetics Co. Ltd., Nippon Zenyaku Kogyo Co. Ltd., Quality Biological Inc., Corning Incorporated.

North America was the largest region in the cell freezing media market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell freezing media market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell freezing media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cell freezing media market by increasing costs of imported cryoprotective agents, pharmaceutical-grade solvents, sterile packaging materials, and filtration components. Academic research institutions, biotechnology companies, and clinical laboratories in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher costs in media formulation and distribution. These tariffs are increasing overall storage and preservation costs. At the same time, they are encouraging domestic formulation of freezing media, local sourcing of excipients, and regional expansion of GMP-compliant manufacturing facilities.

The cell freezing media market research report is one of a series of new reports that provides cell freezing media market statistics, including cell freezing media industry global market size, regional shares, competitors with a cell freezing media market share, detailed cell freezing media market segments, market trends and opportunities, and any further data you may need to thrive in the cell freezing media industry. This cell freezing media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell freezing media is a specialized solution used to preserve living cells at extremely low temperatures, typically in liquid nitrogen, to retain their viability and functional properties over long durations. It generally contains cryoprotective agents that inhibit ice crystal formation and protect cell structure during freezing and thawing. This media supports the long-term storage of biological samples for research, therapeutic, and diagnostic purposes, ensuring cells remain viable and can be successfully recovered after thawing.

The main types of cell freezing media include dimethyl sulfoxide (DMSO), glycerol, sucrose, ficoll, and serum-based media. Dimethyl sulfoxide (DMSO) is an organic solvent commonly used as a cryoprotectant in cell freezing media to reduce ice crystal formation and maintain cell viability during cryogenic storage. The cell culture types involved include suspension cell culture, 2D cell culture, 3D cell culture, and others, and these products are distributed through channels such as direct sales, distributors, e-commerce platforms, retail outlets, and specialized scientific instrumentation suppliers. They are applied in stem cell research, embryonic cell preservation, hematopoietic cell preservation, tissue sample storage, gene therapy applications, and others, and are used by end users including academic research institutions, biotechnology companies, pharmaceutical companies, clinical laboratories, and contract research organizations (CROs).

The cell freezing media market consists of sales of cryovials, freezing containers, cryogenic storage bags, controlled-rate freezers, cryopreservation buffers, and freezing solution kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.